U.S., Jan. 10 -- ClinicalTrials.gov registry received information related to the study (NCT07328191) titled 'Quality of Life-Guided Transfusion in Refractory MDS or AML' on Dec. 26, 2025.
Brief Summary: Patients with refractory myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML) in exclusive palliative care frequently receive red blood cell transfusions based on hemoglobin thresholds, despite limited evidence of clinical benefit in this setting.
This prospective randomized study compares a standard hemoglobin-based transfusion strategy to a quality-of-life-guided strategy using the EQ-5D-5L questionnaire, with the aim of reducing transfusion burden while maintaining patient safety and quality of life.
Study Start Date: Feb. 0...